• New funding brings total Series B raise to $75.2 million
• Novo Holdings led round, joined by Venrock, DROIA, Osage University Partners, Lightstone and Celgene Corpo­ra­tion
• RAD51 in­hib­i­tor CYT-0851 now being eval­u­ated in patients with re­lapsed, re­frac­tory B-cell malig­nan­cies and ad­vanced solid tumors

Lexington, MA (Press Release) – Cyteir Thera­peutics, a leader in the discovery and devel­op­ment of next-generation syn­thet­ic lethal ther­a­pies for cancer, today announced the close of an addi­tional $40.2 million in the com­pany's Series B financing, for a total of $75.2 million in this financing. The addi­tional funding will be used to ex­pand the clin­i­cal in­ves­ti­ga­tion of Cyteir's first-in-class RAD51 in­hib­i­tor and lead com­pound, CYT-0851, and to identify new targets using the com­pany's novel gain-of-function syn­thet­ic lethality screen­ing plat­form.

Novo …